Prof Peter JohnsonClinician

Biography

Professor Peter Johnson CBE MD FRCP FMedSci is National Clinical Director for Cancer at NHS England, a post he has held since 2019, and Professor of Medical Oncology at the University of Southampton. He is also Chair of the UK Office for Life Sciences Cancer Healthcare Goals programme. His work at NHS England spans policy aimed at improving cancer survival, with a particular focus on earlier and faster diagnosis and treatment. He was previously Chief Clinician for Cancer Research UK (2008–2017) and Director of the Francis Crick Institute Cancer Research Network (2017–2019). He qualified in medicine from Cambridge and St Thomas's Medical School, completed oncology training and doctoral research at St Bartholomew's Hospital, and is a medical oncologist specialising in lymphoma, with research interests in immunotherapy, lymphoma biology, precision medicine, and clinical trials.

References

1. 1.NHS England – Professor Peter Johnson (author page) — Current role as National Clinical Director for Cancer at NHS England; Chair of UK Office for Life Sciences cancer goal; research interests; former Chief Clinician at CRUK
2. 2.Southampton Professor to lead national cancer programme – University of Southampton — Appointment as National Clinical Director for Cancer at NHS England and Improvement in 2019; role chairing Clinical Advisory Group; continued clinical work in lymphoma at UHS
3. 3.Cancer Healthcare Goals – GOV.UK — Role as chair of Cancer Healthcare Goals programme; tenure as National Clinical Director since 2019; prior roles at Francis Crick Institute and Cancer Research UK; MANIFEST grant
4. 4.Professor Peter Johnson – University Hospital Southampton NHS Foundation Trust — Clinical background; CBE awarded 2016; accreditation in medical oncology; experience in lymphoma including high-dose therapy and stem cell transplantation

Expertise

Cited on

• Hospital discharge / bed-blocking
• Cancer

Stated areas of expertise

• Cancer diagnostics and early detection
• Cancer immunotherapy
• Lymphoma and haematological oncology
• Cancer clinical trials
• NHS cancer policy and strategy
• Personalised cancer vaccines

Notable achievements

• Appointed National Clinical Director for Cancer at NHS England in 2019, chairing the Clinical Advisory Group providing clinical input into the National Cancer Programme. Source ↗
• Awarded CBE in 2016 for services to medicine and higher education, recognising his leadership in oncology and immunotherapy. Source ↗
• Instrumental in establishing the UK's first dedicated Centre for Cancer Immunology at the University of Southampton. Source ↗
• Led the NHS Cancer Vaccine Launch Pad (CVLP), established in September 2023 to fast-track patient access to mRNA personalised cancer vaccine and immunotherapy clinical trials, aiming to provide up to 10,000 patients with personalised cancer treatments by 2030. Source ↗
• Chair of the UK Office for Life Sciences Cancer Healthcare Goals programme, co-funding a £9m grant with the Medical Research Council to the MANIFEST immunotherapy platform. Source ↗

What they’ve said

• “This decision provides another welcome treatment option for patients living with an advanced and aggressive form of prostate cancer.”

  clinical director for cancer at NHS England · Hospital discharge / bed-blocking · 27 Aug 2026 · Prostate cancer drug that can halve death risk to be offered to thousands in England ↗

• “There is growing evidence of the benefits of physical activity for people affected by cancer and our specialist teams across the country are there to help patients at each stage of their care, including supporting them to be as active as possible before, during and after treatment.”

  NHS England's National Director for Cancer · Hospital discharge / bed-blocking · 27 Aug 2026 · Offer cancer patients exercise on NHS, major charity urges ↗

• “The NHS will continue to work hard to offer people the most effective and evidence-based treatments, with several new prostate cancer drugs rolled out over the last five years.”

  national clinical director at NHS England · Hospital discharge / bed-blocking · 27 Aug 2026 · NHS expands access to prostate cancer drug in England to save thousands of lives ↗

• “This is a major step forward in bowel cancer detection and will help save hundreds more lives from this devastating disease. Testing at a lower level threshold will now provide a better early warning system for bowel cancer, helping us to spot and treat cancers earlier, often picking up problems before symptoms occur.”

Source references

1. Prostate cancer drug that can halve death risk to be offered to thousands in Englandtheguardian.com · 27 Aug 2026
2. Offer cancer patients exercise on NHS, major charity urgestheguardian.com · 27 Aug 2026
3. NHS expands access to prostate cancer drug in England to save thousands of livestheguardian.com · 27 Aug 2026
4. NHS to increase sensitivity of bowel cancer test in Englandtheguardian.com · 27 Aug 2026
5. NHS England to trial AI and robotic tools to detect and diagnose lung cancertheguardian.com · 27 Aug 2026

Contact & links

• Staff pagehttps://www.england.nhs.uk/author/professor-peter-johnson/
• Staff pagehttps://www.southampton.ac.uk/people/5wy7cm/professor-peter-johnson
• Staff pagehttps://www.uhs.nhs.uk/for-patients/find-your-consultant/professor-peter-johnson
• ORCIDhttps://orcid.org/0000-0002-1343-2054published here ↗

Organisational contact points only, each taken from a page the organisation publishes itself. No personal or direct contact details are held or shown.